| P50 | author | Stefan Kluge | Q21072400 |
| P2093 | author name string | Valentin Fuhrmann | |
| | Holger Rohde | |
| | Marcel Simon | |
| | Juri Katchanov | |
| | Dominic Wichmann | |
| | Martin Christner | |
| | Azien Laqmani | |
| | Maria Schroeder | |
| | Charles Wijaya | |
| P2860 | cites work | Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease | Q28251330 |
| | Invasive aspergillosis in the intensive care unit | Q28306909 |
| | Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis | Q28540254 |
| | Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. | Q34085884 |
| | Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes | Q34559978 |
| | Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes | Q35131913 |
| | Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients | Q35807013 |
| | Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study | Q36633947 |
| | Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome | Q36686780 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Invasive aspergillosis in the intensive care unit | Q38066616 |
| | Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial | Q38103680 |
| | Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient | Q38118604 |
| | Diagnostic yield and safety of CT scans in ICU. | Q41593839 |
| | Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients | Q41998776 |
| | Invasive aspergillosis in the ICU: an emerging disease | Q44610230 |
| | A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients | Q46059175 |
| | Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality | Q49124894 |
| | Diagnostic criteria for invasive pulmonary aspergillosis in critically ill patients. | Q51348218 |
| | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. | Q54394711 |
| | Aspergillosis | Q55951920 |
| | Galactomannan in Bronchoalveolar Lavage Fluid | Q57559940 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis | Q86221095 |
| | [Fungal infections in hematology patients and after blood stem cell transplantation: prophylaxis and treatment] | Q86575356 |
| | Aspergillosis in the ICU - The new 21st century problem? | Q92929057 |
| P433 | issue | 1 | |
| P304 | page(s) | 139 | |
| P577 | publication date | 2016-05-10 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study | |
| P478 | volume | 20 | |